Sorafenib and Xgeva drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Sorafenib (sorafenib) and Xgeva (denosumab). Common drug interactions include headache among females and osteonecrosis of jaw among males.

The phase IV clinical study analyzes what interactions people have when they take Sorafenib and Xgeva. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Sorafenib?

Sorafenib has active ingredients of sorafenib. eHealthMe is studying from 3,201 Sorafenib users. Check the latest studies of Sorafenib.

What is Xgeva?

Xgeva has active ingredients of denosumab. It is often used in breast cancer. eHealthMe is studying from 37,717 Xgeva users. Check the latest studies of Xgeva.

On Jul, 12, 2026

17 people who take Sorafenib and Xgeva together, and have interactions are studied.

What are the common drug interactions of Sorafenib and Xgeva, by gender? *:

female:

Headache (pain in head)
Lung disorder (lung disease)
Metastases to central nervous system (cancer spreads to central nervous system)
Metastasis (spreadable cancer to other organ from origin)
Nausea (feeling of having an urge to vomit)
Vision blurred
Vomiting
Osteonecrosis of jaw (death of bone of jaw)

male:

Osteonecrosis of jaw (death of bone of jaw)
Malignant neoplasm progression (cancer tumour came back)
Neuropathy peripheral (surface nerve damage)
General physical health deterioration (weak health status)
Thrombocytopenia (decrease of platelets in blood)
Pain in extremity
Death
Diarrhoea
Essential hypertension (primary hypertension)
Focal segmental glomerulosclerosis (scar tissue that forms in parts of the kidney called glomeruli)

What are the common drug interactions of Sorafenib and Xgeva, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Headache (pain in head)
Lung disorder (lung disease)
Metastases to central nervous system (cancer spreads to central nervous system)
Metastasis (spreadable cancer to other organ from origin)
Nausea (feeling of having an urge to vomit)
Vision blurred
Vomiting
Death

20-29:

Death

30-39:

n/a

40-49:

Malignant neoplasm progression (cancer tumour came back)
General physical health deterioration (weak health status)
Thrombocytopenia (decrease of platelets in blood)

50-59:

n/a

60+:

Osteonecrosis of jaw (death of bone of jaw)
Death
Diarrhoea
Essential hypertension (primary hypertension)
Focal segmental glomerulosclerosis (scar tissue that forms in parts of the kidney called glomeruli)
Hypotension (abnormally low blood pressure)
Neuropathy peripheral (surface nerve damage)

What are the existing conditions these people have? *

Renal Cell Carcinoma (a kidney cancer): 5 people, 29.41%
Metastases To Bone (cancer spreads to bone): 3 people, 17.65%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 2 people, 11.76%
Medullary Thyroid Cancer (type of thyroid cancer that develops in the parafollicular cells of the thyroid gland): 2 people, 11.76%
Sarcoma Metastatic (rare cancers that develop in the muscle, bone, nerves, cartilage, tendons, blood vessels and the fatty and fibrous tissues spreads to other parts): 1 person, 5.88%
Renal Disorder (kidney disease): 1 person, 5.88%
Renal Cancer Metastatic (cancer of kidney spreads to other part): 1 person, 5.88%
Papillary Thyroid Cancer: 1 person, 5.88%
Osteosarcoma Metastatic (a cancerous (malignant) bone tumour can spreads to other parts): 1 person, 5.88%
Metastatic Neoplasm (spreadable cancer tumour): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Sorafenib and Xgeva?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously